Clinical Trials

768 enrolled

BreastGastrointestinal

Adenocarcinoma Of Esophagus, Breast Neoplasms, Colorectal Neoplasms

NCT03424005 2026-03-16

Morpheus-panBC

792 enrolled

Breast Neoplasms

NCT06469944 2026-03-16

MK-3475-06C

160 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT06134375 2026-03-12

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

204 enrolled

Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT04333706 2026-03-10

EMPOWER

65 enrolled

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT05849480 2026-02-05

A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)

60 enrolled

Bile Duct Neoplasms, Biliary Tract Neoplasms

NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

500 enrolled

Solid Cancer

NCT07007559 2026-02-03

ASPEN-09

80 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT06741644 2026-01-09

A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors

660 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT04564898 2026-01-08

TriComB

48 enrolled

Colorectal Cancer Metastatic

NCT04711824 2025-12-23

SOLARA

41 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT04495296 2025-12-19

A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

320 enrolled

Advanced Cancer

NCT06703177 2025-12-03

A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors

876 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT06247995 2025-11-06

NeoB-Cap1

58 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT05609370 2025-10-02

A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

113 enrolled

Colorectal Neoplasms

NCT04701281 2025-09-18

SYS-CAPLIOX

Phase 1/2 Terminated

5 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT05990543 2025-09-08

Combination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal Cancer

59 enrolled

Recurrence, Colorectal Neoplasms

NCT04031872 2025-09-05

LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615)

Phase 1/2 Withdrawn

Colorectal Cancer Metastatic

NCT06208410 2025-07-25

A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors

306 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT04963088 2025-06-26

TALENT

Phase 1/2 Completed

65 enrolled

Stomach Neoplasms

NCT07040059 2025-06-26

A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

18 enrolled

HER 2 Positive Gastric Cancer

NCT01349088 2025-05-02

Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer

Phase 1/2 Withdrawn

Breast Neoplasms

NCT05535413 2025-04-25

UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases

30 enrolled

CNS

Brain Neoplasms

NCT02795988 2025-04-16

A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer

Phase 1/2 Completed

64 enrolled 20 charts

Adenocarcinoma, Gastrointestinal Neoplasms, Neoplasm Metastasis

NCT03377387 2025-04-15

Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer

34 enrolled

Breast Neoplasms

NCT03213002 2025-04-09

CAPTEM

Phase 1/2 Not yet recruiting

67 enrolled

CNS

Brain Neoplasms, Glioblastoma, Neoplasms

NCT06888674 2025-03-21

Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.

60 enrolled